Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

May 9, 2025
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • DNA-Tales
  • Senolytic drugs: A way to get rid of senescent cells

Dogs distinguish intentional from unintentional behaviour

Humpback whales show great vocal control and flexibility in singing

Senolytic drugs: A way to get rid of senescent cells
  • Biotechnopedia
  • DNA-Tales

Senolytic drugs: A way to get rid of senescent cells

DNA tales September 11, 2021September 10, 2021

Priyanka Saha, Amity University Kolkata

Introduction

Senolytics are a special class of drugs that eliminate old or senescent cells (SC) in the body. They are developed to prevent or delay age-related diseases in humans. The word senolytics is connected to “Senostatic” which refers to suppressing senescence. Most of the senolytic agents are in the early clinical human trials for a better understanding of their effectiveness in achieving good health.

Senolytics have been potentially identified as a new way for curing age-related malfunction and disorders in preclinical research. They are known to reduce the number of senescent cells, inflammation, and infirmity in old people. The major senolytic compounds are the reutilized anti-cancerous molecules, like Navitoclax, Quercetin, Fisetin, and Dasatinib.

Most of the senolytic drugs have been observed to prevent or delay cancers, cardiovascular, neuropsychiatric, liver, kidney, musculoskeletal, lung, eye, hematological, skin disorders, and complications related to organ transplantation and radiation from cancer treatment. These drugs are also in primary clinical trials for the treatment of diabetes, Alzheimer’s disease, COVID-19, osteoarthritis, osteoporosis, pulmonary fibrosis, eye problems, and bone marrow transplant.

The Discovery of Senolytics

Senescent cells depict resistance towards apoptosis. This apoptosis resistance takes place despite the production of pro-apoptotic SASP (Senescence Associated Secretory Phenotype) factors by the senescent cells.

The hypotheses that were taken into account during the discovery of senolytic drugs are:

1) Senescent cells resist apoptosis which increases pro-survival-anti -apoptotic defenses, and

2) sometimes senescent cells act like cancer cells that do not multiply, are resistant to apoptosis, and show characteristic metabolic changes.

Senescent cells follow SCAP (Senescent cell Anti-Apoptotic Pathway) network which prevents their removal, and this network is extensively found in senescent cells as compared to non-senescent cells. Depending on the type of the senescent cell type, small interfering RNAs (siRNA’s) were effective in decreasing senescent cells viability against anti-apoptotic regulators.

Bioinformatics tools were used to identify compounds targeting the SCAP network that protects senescent cells from apoptosis. 46 such compounds were identified and most of them are already in use as anti-cancerous agents. This comprises Dasatinib (D, a tyrosine kinase inhibitor), Quercetin (Q, flavonoid, makes apple peel taste bitter), and Fisetin (F, flavonoid). The tyrosine kinase inhibitor Dasatinib promotes apoptosis created by dependence receptors (ephrins) by inhibiting Src Kinase whereas the flavonoids act in part by inhibiting BCL-2 members like BCL-xL, HIF-1a, and many other SCAP components. Dasatinib and Quercetin, when used together have the potential to induce apoptosis in both senescent human primary adipocyte progenitor cells and senescent HUVEC’s.

The first senolytic drugs (D, Q, F) were discovered by bioinformatics to find agents that disable the SCAP network. The second generation of senolytic agents (vaccines, immunomodulators) is being identified using traditional drug discovery methods and other drug discovery methods.

The Need for Senolytic Drugs

Senescent cells are quite harmful at old age. These cells are not able to divide or multiply like other cells but can manage to remain alive. Senescent cells affect tumor suppression, wound healing, embryonic/placental growth, and plays a pathological role in age-released diseases as well. As we grow old, these cells get stored at sites of multiple chronic disorders which results in morbidity, mortality, and deterioration of human health. The deleterious senescent cells are resistant to apoptosis by having up-regulation of the anti-apoptotic pathway which defends them against their SASP. This up-regulation allows them to survive for a long time and to kill the healthy cells around them. Senolytics temporarily impair these SCAPs, resulting in apoptosis of those cells with a tissue destructive SASP. As these cells take weeks to re-accumulate or store, senolytics can be administered discontinuously – a ‘hit-and-run’ approach.

Some Potential Senolytic Candidates

1) Senolytic FOXO4-related peptides: When a protein named p53 is reserved in the nucleus by FOXO4, it results in cellular senescence. Later, the p53-FOXO4 interaction is broken down by a peptide which releases p53 in the cytosol and triggers cell death.

2) Navitoclax: Also known as ABT-263, is a chemotherapeutic drug that has the potential to eliminate senescent hematopoietic stem cells (HSCs), muscle stem cells and mesenchymal stromal cells (MSCs).

3) Fisetin: It is a plant-based flavanol belonging to the flavonoid group. It reduces senescence in specific cells in rodents and human adipose tissue cells which indicates that it is highly cell-specific.

4) Dasatinib and Quercetin (D+Q) combination: It is the first identified senolytic drug that showed an impact on the SCAPs and eliminates different kinds of senescent cells in the human body.

5) Piperlongumine (PL): It is a compound derived from Piper species that has numerous effects on tumors, diabetes, pain, neurodegenerative and psychiatric disorders. It decreases cognitive impairment and improves hippocampal function in aged rodents. Although its clinical trial for human usage is still ongoing.

The Potential of Senolytics to Modify Geriatric Medicine

Effective senolytics and its associated agents that delay aging have the potential to transform geriatric medicine. These drugs may have the ability to increase healthspan and delay or alleviate chronic disorders which otherwise cause morbidity, immobility, and decreasing health in people across the globe. Senolytics are believed to delay or treat geriatric problems, along with sarcopenia, immobility, and cognitive disorders.

The use of senolytics in geriatric medicine could modify the treatment and health services in old age people by increasing their lifespan and curing the diseases faced by them. The basics of these drugs have been reviewed and they have moved-up in the clinical trials in the last few years. For its successful usage, clinical geriatricians and scientists dealing biology of aging are needed to study and reveal insights into this topic, to unravel the entire pathway of the senolytics targeting the aging process and senescent cells, while abiding by of social and bioethical norms.

Clinical Strategies To Be Adopted

Modern clinical trial strategies are necessary to understand senolytic drugs’ function in removing senescent cells and delaying the aging process. Parameters such as lifespan cannot be tested in humans. According to the geoscience hypotheses, if a candidate drug targets the fundamental aging process, then it also potentially affects a wide range of pre-existing chronic conditions and age-related problems. The potential clinical trial includes:

A) Concurrent relief of multiple disorders/diseases: Humans, especially the old ones suffer from multiple diseases. The use of senolytics can alleviate disease-related problems like glucose intolerance, cognitive impairment, joint Pai caused by osteoarthritis, hypertension, or low carotid flow. These drugs can also delay the onset of a second age-related disorder for those who are already suffering from one disorder.

B) Treatment of conditions with localized senescent cell accumulation: Disorders like osteoarthritis, idiopathic pulmonary fibrosis, and retinopathies are related to the accumulation of senescent cells. This opens the way for the usage of senolytic drugs in humans.

C) Treatment of accelerated aging-like problems: Senolytics targeting the basic aging process may be useful in treating conditions related to accelerated aging-like phenotypes, including chemotherapy to bone marrow transplantation or childhood cancers, human immunodeficiency infection, or obesity.

D) Reliving fragility: Senolytics may be tested in short-term clinical trials in older adults with frailty which will determine strength, gait, body weight, and other parameters to upgrade.

E) Alleviating potentially fatal disease: Diseases like idiopathic pulmonary fibrosis and primary sclerosis cholangitis, that have no effective treatment are believed to be caused due to accumulation of senescent cells. Senolytic drugs are expected to be a cure for this disease by targeting the senescent cells.

Summary

The main motive behind using senolytic drugs is to eliminate senescent cells that cause an array of health-related issues with age. These agents could interfere and delay, prevent, or alleviate multiple age-related conditions and chronic diseases, leading to increase in lifespan and health quality. For human use, senolytic drugs are still under clinical trial for administrating their effectiveness and toxicity level, for their usage to prevent or delay senescence. Unless such clinical trials are well-established, senolytics should not be used or recommended by physicians for any treatment among general populations. Till then senolytics should be only used and administered carefully for research and developmental purposes under proper supervision of experts, in appropriate laboratorical conditions.

Also read: Dogs distinguish intentional from unintentional behaviour

References:

  1. Kirkland, J. L., & Tchkonia, T. (2020). Senolytic drugs: From discovery to translation. Journal of internal medicine, 288(5), 518-536.https://doi.org/10.1111/joim.13141
  2. Zhu, M., Meng, P., Ling, X., & Zhou, L. (2020). Advancements in therapeutic drugs targeting of senescence. Therapeutic Advances in Chronic Disease, 11, 2040622320964125. https://doi.org/10.1177%2F2040622320964125
  3. Scharping, N. (2020). Senolytics: A New Weapon in the War on Aging. Discover Magazine. https://www.discovermagazine.com/health/senolytics-a-new-weapon-in-the-war-on-aging
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Related

Tagged Alzheimer’s disease Apoptosis Cardiovascular disorder clinical trials COVID-19 Dasatinib Fisetin Flavonoid Geriatric Hematological skin disorder Hippocampal function HSC HUVEC inflammation MSc Musculoskeletal disorder Navitoclax Neuropsychiatric disorder osteoarthritis pulmonary fibrosis Quercetin Sarcopenia senescence senolytic agents senolytic drugs senolytics

One thought on “Senolytic drugs: A way to get rid of senescent cells”

  1. Pingback: The influence of age on the genetic risk of common illnesses - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Humpback whales show great vocal control and flexibility in singing

BioTech Today September 13, 2021

Nimrit Palan, Mumbai University Humpback whale songs are similar to bird songs in that they sing to attract other whales for mating or to warn their competitors. They sing with great changes in vocal flexibility. This explains why human labels like crying, chirping and moaning are insufficient for a species that is capable of more advanced […]

Humpback whales

Related Post

  • Biotechnopedia
  • DNA-Tales

Different Coronavirus Strains and Their Severity

DNA tales July 5, 2021July 5, 2021

Camelia Bhattacharyya, Amity University Kolkata The coronavirus disease or COVID is something that is shaking the entire portrait of the lives of people in the world right now. This single-stranded, positive-sensed, enveloped virus has given rise to a pandemic in the 21st century. In such a situation, learning about the different mutants, variants, and strains […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Biotechnopedia
  • DNA-Tales

Fluid rheology: As you flow, so shall your importance grow!!!

bioxone March 14, 2021March 14, 2021

Camelia Bhattacharyya, Amity University Kolkata  “A matter is something that takes up space and has volume. It can be classified into solid, liquid, and gas” – we’ve come across this sentence as early as our elementary school days. Then as we grew up, we understood the differences among these matters, the different properties and performed […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Biotechnopedia
  • DNA-Tales

The mind in the midnight hour

BioTech Today June 22, 2021June 22, 2021

Priasha Dutta, Amity University Kolkata Stages of sleep: Various research studies have elucidated the various aspects of the mind in the midnight hour. While we sleep and have dreams, our brain is directly involved in regulating our sleep cycles and monitoring sleep and dream quality. Sleep has two stages: (i) REM (rapid eye movement) (ii) […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy